| Jul 30 |
Guardant Health secures FDA approval for Shield test
|
| Jul 30 |
Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?
|
| Jul 29 |
FDA approves Guardant Health's blood test for colon cancer
|
| Jul 29 |
Guardant Health Gets FDA Nod on Colorectal Cancer Blood Test
|
| Jul 29 |
FDA Greenlights Guardant Health's Shield Blood Test, Analyst Cautious on Adoption
|
| Jul 29 |
Guardant wins FDA approval for colon cancer blood test
|
| Jul 29 |
Guardant Health stock jumps as FDA clears blood test for colorectal cancer screening
|
| Jul 29 |
Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
|
| Jul 24 |
Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024
|
| Jul 23 |
Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance
|
